Prominent Runners: II-VI Incorporated (NASDAQ:IIVI) & Pain Therapeutics, Inc. (NASDAQ:PTIE)

4

II-VI Incorporated (NASDAQ:IIVI)

II-VI Incorporated designs, manufactures and markets optical and opto-electronic components, devices and materials for infrared, near-infrared, visible light, x-ray and gamma ray instrumentation. The Company’s infrared optics business manufactures optical and opto-electronic components sold under the II-VI brand name and used primarily in CO2 lasers. The Company’s near-infrared optics business manufactures near-infrared & visible light products for industrial, scientific, military & medical instruments and laser gain materials and products for solid-state YAG and YLF lasers at the Company’s VLOC subsidiary. The Company’s military infrared optics business manufactures infrared products for military applications under the Exotic Electro-Optics brand name.

II-VI Incorporated (NASDAQ:IIVI)’s Financial Overview

II-VI Incorporated (NASDAQ) surged 0.19% yesterday to close its trading session at $37.66. The company has 1 year Price Target of $50.85. II-VI Incorporated has 52-Week high of $50.75 and 52-Week Low of $29.31. The stock touched its 52-Week High on 50.75 and 52-Week Low on 29.31. The stock traded with the volume of 722057 shares yesterday. The firm shows the market capitalization of $2.36 Billion.

II-VI Incorporated (NASDAQ) reported its last quarterly earnings on 12/30/2018 where the firm reported its Actual EPS of $0.71/share against the analyst consensus estimate of $0.67/share. The difference between the actual and expected EPS is $0.04 a share with a surprise factor of 6%.

The firm is trading with SMA20 of 7.38 Percent, SMA50 of 10.78 Percent and SMA200 of -8.67 percent. II-VI Incorporated has P/S value of 1.86 while its P/B value stands at 2.29. Similarly, the company has Return on Assets of 5 percent, Return on Equity of 8.7 percent and Return on Investment of 7.1 Percent. The company shows Gross Margin and Operating Margin of 39.4 percent and 11 percent respectively.

The Stock currently has Analyst’ mean Recommendation of 2.1 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 10 analysts offering 12-month price forecasts for II-VI Inc have a median target of 48.00, with a high estimate of 61.00 and a low estimate of 40.50. The median estimate represents a +27.46% increase from the last price of 37.66.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

Pain Therapeutics, Inc. (NASDAQ:PTIE)

Pain Therapeutics is developing a new generation of opioid painkillers. Opioids are drugs derived from the poppy plant. The company uses technology to reformulate opioid drugs, such as morphine, into new painkillers with improved clinical benefits. The company has four opioid painkillers in Phase II clinical trials. The company believes its drugs offer enhanced pain relief, fewer adverse side effects and reduced tolerance and addiction compared to existing opioid painkillers.

Pain Therapeutics, Inc. (NASDAQ:PTIE)’s Financial Outlook

The 1 analysts offering 12-month price forecasts for Pain Therapeutics Inc have a median target of 23.75, with a high estimate of 23.75 and a low estimate of 23.75. The median estimate represents a +2,161.90% increase from the last price of 1.05.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

The Stock surged 1.94% and closed its last trading session at $1.05. The company has the market capitalization of $19.88 Million. The stock has 52-week high of $10.87 and 52-Week low of $0.76. The firm touched its 52-Week high on 10.87 and 52-Week low on 0.76. The company has volume of 215558 shares. The company has a total of 18.93 Million shares outstanding.

Pain Therapeutics, Inc. (NASDAQ) in the last quarter reported its actual EPS of $-0.64/share where the analyst estimated EPS was $-0.47/share. The difference between the actual and Estimated EPS is $-0.17. This shows a surprise factor of -36.2 percent.

The company has YTD performance of 23.53 percent. Beta for Pain Therapeutics, Inc. stands at 1.93 while its ATR (average true range) is 0.09. The company has Weekly Volatility of 7.09%% and Monthly Volatility of 8.18%%.

Pain Therapeutics, Inc. has distance from 20-day Simple Moving Average (SMA20) of -7.41%, Distance from 50-Day Simple Moving Average of -0.38 percent and Distance from 200-Day Simple Moving Average of -65.51%.

The Company currently has ROA (Return on Assets) of -63.1 percent, Return on Equity (ROE) of -68.4 Percent and Return on Investment (ROI) of 0% with Gross margin of 0 percent and Operating & Profit margin of 0% and 0% respectively.

SHARE